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Background: Using a cross-database integrative approach, we performed an epidemiological analysis in a representative
region of central Poland to evaluate the availability of radiotherapy (RTx) and overall survival of adult patients undergoing
RTx for cancer.
Methods: Epidemiological data on cancer incidence in the 2005–2012 period were obtained from the Nationwide
Cancer Registry. Using data from the Ministry of Internal Affairs, we collected survival information of all patients treated in
the only centre providing RTx for a region inhabited by approximately 2.6 million people.
Results: After filtering out individuals on the basis of exclusion criteria, the final dataset covered 17,736 patients.
Availability of RTx increased marginally, from 23.5% (2005) to 24.4% (2011, R = 0.39, p = 0.38), with the highest values
noted in patients with cervical (78.5%), prostate (70.6%) and breast cancer (62.7%). However, due to the decreasing
population of the region, we noted increasing disparity in the likelihood of receiving RTx depending on the patient’s
area of residence, with rural areas becoming progressively more neglected. The best prognosis was noted among
patients with breast or prostate cancer with 5-year OS rates reaching 81.2% and 83.3%, respectively. Multivariate analysis
controlling for type of diagnosis and patient age showed a time-dependent improvement in outcomes (HR(95% CI): 0.96
(0.94-0.98); p < 0.0001).
Conclusions: Availability of RTx in Poland is still below that reported by developed European centres. Survival of patients
undergoing radical RTx has gradually improved, although it is still below that of leading RTx departments, potentially
due to delayed diagnosis or organisational barriers, necessitating further investigations.Background
Population-based survival studies are a cornerstone
of assessments of healthcare system efficacy [1]. The
EUROCARE network collects survival data of patients
with malignancies from European countries, thus allow-
ing unbiased comparisons amongst countries and conti-
nents [2]. However, despite recent advances in computer
use in clinical practice, Poland is still struggling with
digitization of its healthcare registries, distribution of
radiotherapeutic equipment and staff limiting the scope
of epidemiological analyses of the Polish population [3].* Correspondence: justyna.chalubinska-fendler@e.umed.lodz.pl
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article, unless otherwise stated.This makes it extremely difficult to perform comparative
analyses of prevalence, whilst estimation of survival is
nearly impossible. However, an opportunity to perform
such analyses arose owing to the highly centralised
network of radiation oncology departments which exists
in the publicly funded oncological treatment system of
Poland. Within the 16 administrative regions of Poland
(voivodeships) there are only 23 radiation oncology cen-
tres, which thus constitute foci for epidemiological ana-
lyses in oncology. In the Lodzkie Voivodeship, a single,
large centre oversees radiotherapy (RTx) for all eligible
patients with cancer, and has been running a compu-
terised medical database since January 2005. We have
used this resource to demonstrate the development of a
framework for nationwide integrative database construc-
tion and present the methodology and efficiency of aMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ability and survival of cancer patients.
Methods
The study aimed to synthesise oncological data from
regional and national levels, integrate it with place of
residence information and provide an epidemiological
reference on radiotherapy accessibility and survivorship
in the Lodzkie Voivodeship. Epidemiological data on the
number of newly diagnosed cancer cases in the Lodzkie
Region were obtained from the nationwide cancer regis-
try (data available for 2005–2012). This dataset is col-
lated using reports from oncology centres and financial
data of the National Health Fund. The registry is over-
seen by the National Centre of Oncology (NCO). The
NCO dataset was previously used for epidemiological
reports [4,5], and we used it here as the reference for
evaluation of RTx availability.
To analyse RTx-related data collected at department
level, we used the computer-based dataset of all patients
treated in the Department of Radiotherapy of the Medical
University of Lodz During the study period, this depart-
ment was the only specialist radiation oncology centre for
the Lodzkie Voivodeship, a region inhabited by 2.53-2.58
million people according to Central Statistical Office data
(http://www.stat.gov.pl/bdlen/app/strona.html?p_name=
indeks). The department’s database was installed in
October 2004 and became the principal data storage re-
source for the department in January 2005. The database
was constructed using Microsoft Access architecture
(Microsoft, Redmond, WA, USA). It is continuously up-
dated on a daily basis and manually curated. Data entry is
performed by a team of three dedicated medical secretar-
ies, and correctness of the medical records is verified by
each patient’s attending doctor before the patient’s dis-
charge. Data on diagnosis is coded using the ICD-10 clas-
sification as legally required by the National Health Fund.
Since no long-term malfunctions of the database occurred
during the analysed period of 1 January 2005–14 July
2012, we assumed that the database covers 100% of
patients undergoing RTx. The number of patients from
urban and rural areas, treated per year, procedures per-
formed within the centre during that period, and times of
introduction of novel techniques and equipment upgrades
are shown in Additional file 1: Figure S1. Rural residents
were individuals who inhabited rural areas or towns with a
population density lower than 150 individuals/km2 as
designated by the Central Statistical Office.
Survival data were obtained by integrating the depart-
ment’s dataset with the nationwide, centrally-curated ad-
ministrative PESEL database. The PESEL is the personal
identification number assigned to each Polish citizen and
used for most administrative purposes, including the
healthcare system. Individual survival data are overseen bythe Ministry of Internal Affairs. The repository is access-
ible to public medical institutions and we were thus able
to obtain individual data confirming whether the desig-
nated patients were alive or dead at the time of database
query (14 July 2012). This date constituted the final obser-
vation date – patients alive on that day were thus consid-
ered as censored observations. As the PESEL database is
the main source of information on individual survival, we
surmised that it can be used for survival analysis purposes
without further validation. The latency of administrative
data collection is no more than 14 days. Where possible,
we cross-matched the administrative records with data on
earlier studies performed in the centre [6-8], obtaining
100% concordance of survival data.
Patients could be referred to the department from all
hospitals or clinics in the region following initial surgery
or chemotherapy. Because the exact date of cancer diag-
nosis by histopathological examination was not available
for the whole dataset due to disseminated data storage,
the date of RTx initiation was established as the observa-
tion start for the analyses covered herein.
In order to make the analysis uniform, we excluded indi-
viduals who: were under 18 years of age at the time of RTx
initiation; had undergone an earlier course of RTx; had
received RTx for diseases other than cancer; had incorrect,
incomplete or missing data on the date of RTx start or
were impossible to match with the PESEL database.
The department’s database was expanded to cover
demographic data on each patient’s address as well as in-
formation on total radiation dose and fractionation regi-
men, allowing for future in-depth clinical analyses. The
patients were further divided into ones who received rad-
ical treatment, (intention-to-treat radiotherapy) and ones
that received palliative treatment (for symptom relief).
During the period covered by the analysis, several patients
received concurrent chemotherapy in accordance to
tumour-specific guidelines and therapeutic protocols de-
pending on the attending oncologist’s discretion. Concur-
rent chemoradiation was given for cervical cancer, rectal
cancer, head and neck cancers. In our centre lung cancer
patients were treated with sequential chemoradiation
throughout the analysed period. Small cell lung cancer
patients after sequential chemoradiation with at least
stabilization of a disease were referred for PCI (prophylac-
tic cranial irradiation).
All patients agreed for the use of their clinical data in
epidemiological studies by signing informed consent
forms prior to the initiation of radiotherapy. Bioethics
Committee of the Medical University of Lodz approved
the study’s design.
Statistical analysis
Continuous variables are given as medians with quartile
boundaries (25-75%). Survival analysis was performed
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regression. Hazard ratios (HR) with 95% Confidence
Intervals (95% CI) were computed where possible. Trend
analysis was performed using Pearson’s correlation coef-
ficient. A p value <0.05 was considered as statistically
significant. Statistica 10.0 PL software was used for stat-
istical analysis (StatSoft, Tulsa, OK, USA).
Results
The department’s dataset covered originally 20,034 pa-
tients. After filtering out individuals on the basis of ex-
clusion criteria, the final dataset comprised 17,736
patients for survival analysis. A flowchart showing data-
set development and the numbers of available individ-
uals and reasons for exclusion are presented in Figure 1.
The numbers of patients that began RTx in each of the
analysed years, their exact diagnoses, and type of treat-
ment used are shown in Table 1. The percentage distri-
butions of the 10 most frequent diagnoses are presented
in Additional file 1: Figure S2 (2A for radical RTx and
2B for palliative RTx). Throughout the analysis period,
the percentage of availability by RTx of cancer patients
increased marginally, from 23.52% in 2005 of newly
diagnosed cancer cases to 24.41% in 2011 (R = 0.39, p =
0.38; Additional file 1: Table S1). The median age of the
studied patients was 60.37 (25-75% 53.34-68.12) years,
and 58.41% (N = 10,359) were female and 41.59% (N =
7,377) were male. The age of patients entering RTxFigure 1 Flowchart of data collection and patient selection. The datas
with data on place of residency were entered into region-specific analyses.
used in Poland.correlated linearly with the year of study (r = 0.95; p <
0.001), with a mean increase of 0.41 years per year,
which was statistically significant amongst breast, lung,
prostate, rectal and laryngeal cancer (Additional file 1:
Table S2). However, we noted an increase in the pro-
portion of patients entering radical RTx (R = 0.89; p =
0.0068), which was paired with a proportional decrease
in the proportion of patients undergoing palliative RTx
(R = −0.86; p = 0.0137). Overall, more than 50% of
individuals with cancer of the breast, prostate, rectum
or cervix underwent RTx during the analysis period
(Figure 2A/B). The percentage of newly diagnosed can-
cer patients entering radical RTx was positively cor-
related with the year of diagnosis in the case of breast
(R = 0.89; p = 0.0068), lung (R = 0.75; p = 0.05), prostate
(R = 0.96; p = 0.0005) and rectal cancer (R = 0.89; p =
0.0068; Figure 2C/D). No significant trends were noted
for cancer of the uterus, cervix, brain, larynx, bladder
or non-Hodgkin lymphoma. The decrease in the percent-
age of patients undergoing palliative RTx was statisti-
cally significant for breast (R = −0.96; p = 0.0005), brain
tumours (R = −0.79; p = 0.0362) and laryngeal cancer
(R = −0.93; p = 0.0025; Figure 2E/F). However, the per-
centage of patients with prostate cancer entering pallia-
tive care correlated positively with the year of diagnosis
(R = 0.86; p = 0.0137). No time-dependent changes were
noted for cancer of the lung, cervix, uterus, rectum,
bladder or non-Hodgkin lymphoma.et marked in bold was used in primary outcome analyses. Individuals
RTx – radiotherapy; PESEL – unique personal identification number
Table 1 Number of patients undergoing radical or palliative radiotherapy during the analysed period, according to diagnosis
Radical Palliative Overall
2005 2006 2007 2008 2009 2010 2011 2012 Total 2005 2006 2007 2008 2009 2010 2011 2012 Total
Breast 380 405 470 485 542 591 575 418 3866 125 82 79 84 66 78 56 43 613 4479
Lung 99 72 58 108 150 164 159 127 937 226 187 176 185 204 215 179 109 1481 2418
Prostate 84 109 122 111 152 201 276 153 1208 23 20 24 29 31 52 33 27 239 1447
Uterus 182 185 188 185 160 156 139 98 1293 2 2 1 3 1 2 5 3 19 1312
Cervix 152 150 181 160 156 155 152 83 1189 16 11 7 9 12 5 11 5 76 1265
Rectum 114 105 133 125 137 147 156 103 1020 43 27 27 41 18 31 27 12 226 1246
Brain 71 67 59 75 75 86 53 35 521 35 31 30 32 15 19 15 5 182 703
Larynx 46 77 99 68 66 77 88 47 568 25 32 23 21 10 11 4 3 129 697
Bladder 6 17 13 14 9 17 17 9 102 15 25 20 23 26 17 14 8 148 250
non-Hodgkin lymphoma 22 15 11 34 40 35 32 11 200 6 4 4 9 8 7 4 0 42 242
Stomach 12 7 25 26 40 41 39 24 214 3 4 1 1 0 4 0 2 15 229
Tonsil 16 21 27 18 13 23 27 12 157 14 9 14 11 10 6 2 4 70 227
Myeloma 9 2 6 5 7 9 8 5 51 27 27 20 24 21 17 25 12 173 224
Kidney 17 4 7 6 8 7 3 1 53 19 25 20 20 19 18 31 12 164 217
Hodgkin 39 38 40 13 15 20 18 16 199 2 0 3 0 3 2 1 2 13 212
Skin (non-melanoma) 29 22 15 14 13 19 18 12 142 13 6 6 6 2 5 1 3 42 184
Tongue 14 11 15 19 16 23 14 5 117 20 7 11 10 2 5 6 1 62 179
Pharynx 16 14 19 14 23 13 15 11 125 17 7 9 5 5 0 2 2 47 172
Melanoma 5 2 2 0 7 13 11 9 49 22 7 9 14 11 8 18 4 93 142
Testis 17 12 22 14 24 20 13 8 130 4 1 1 1 0 1 0 0 8 138
Thyroid gland 5 10 3 6 1 6 7 3 41 5 8 5 6 1 0 4 2 31 72
Soft tissue 1 2 3 8 13 11 11 8 57 1 2 1 1 3 4 1 0 13 70
Oral cavity 4 2 7 4 4 10 7 7 45 1 2 3 5 2 6 2 0 21 66
Oesophagus 6 3 2 3 2 3 6 6 31 2 5 7 1 4 3 4 3 29 60
Parotid gland 6 5 3 4 6 8 7 9 48 4 3 1 0 1 1 0 0 10 58
Ovary 2 8 5 1 3 1 3 1 24 4 3 1 6 5 4 7 1 31 55
Colon 0 2 0 0 2 1 1 4 10 6 5 4 5 4 7 3 2 36 46












Table 1 Number of patients undergoing radical or palliative radiotherapy during the analysed period, according to diagnosis (Continued)
Leukaemia 3 3 3 3 4 1 1 1 19 2 1 1 1 1 0 1 1 8 27
Other 56 55 48 48 48 71 81 64 471 31 27 24 24 19 15 29 11 180 651
Unlocalized 4 7 7 7 9 9 7 8 58 36 26 50 45 37 42 25 16 277 335
No Data 11 16 15 13 34 21 14 31 155 9 11 21 25 26 8 5 15 120 275
All diagnoses 1430 1451 1611 1594 1784 1964 1964 1331 13129 761 608 604 648 569 593 516 308 4607 17736












Figure 2 The percentage of patients with specific diagnoses in the region who underwent treatment in the Center throughout the
study period. Percentage of patients with most frequent diagnoses with good (A) or poor (B) prognosis who underwent radiotherapy during
the study period. Percentage of individuals undergoing RTx depending on diagnosis of the ten most frequently diagnosed types of cancer with
good and poor prognosis divided into subgroups of radical (C/D) and palliative (E/F) RTx expressed as percentages of all patients diagnosed with
cancer in the Lodz voivodeship.
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itants in the region decreased from 2,577,465 in 2005 to
2,524,651 in 2012. A small but significant linear decrease
in urbanization (percentage of patients living in townsor cities within the region) by a mean of 0.16% per year
resulted in a drop from 64.61% in 2005 to 63.62% in
2012 (R = −0.98; p < 0.0001). Over the same period, the
number of patients undergoing RTx, both radical and
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rise noted amongst inhabitants of urban areas (Figure 3).
This suggested increasing disparity in the likelihood of
receiving RTx depending on the patient’s area of resi-
dence, with rural areas becoming progressively more
neglected.
The probability of survival increased with the year of
RTx initiation (Figure 4A), and the difference was statis-
tically significant for a linear trend in RTx initiation year
(HR = 0.97; 95% CI 0.96-0.99; p = 0.0013). Predictably,
the diagnosis associated with the worst prognosis was
lung cancer, with 26.26% of patients reaching 5-year sur-
vival. The best prognoses were associated with prostate
and breast cancers (Figure 4B and C; Table 2).
To verify that the impact of time on the improvement
of OS rates was not solely due to the changing distribu-
tion of diagnoses, a multivariate proportional hazard re-
gression model was developed to adjust for age, type of
diagnosis (p < 0.0001) and year of RTx initiation. Results
of the model confirmed the time-dependent improve-
ment of prognosis, which was marginally greater in
magnitude than in a univariate analysis (HR 0.96 95% CI
0.94-0.98; p < 0.0001), whereas older age at diagnosis
was a detrimental factor (HR 1.03 95% CI 1.02-1.03;
Additional file 1: Table S3).
Discussion
The presented results provide reference material for epi-
demiological comparisons of RTx outcomes. Despite
limited clinical data on tumour staging, the summarised
results showed multiple interesting features relating toFigure 3 The number of patients from urban and rural areas undergo
(left Y axis). The right Y axis shows the number of inhabitants in rural or u
using data of the Central Statistical Office.RTx availability, outcomes, and increasing urban/rural
disparity. With regards to RTx availability, we noted that
in cases of prostate cancer, the percentage of patients
entering RTx with intention to treat in 2006 was equal
to that in the United Kingdom [9,10], but then more
than doubled during the analysis period. British esti-
mates using the updated model published by Delaney et al.
suggested that 48.3% of patients diagnosed with cancer
will have an indication to radiotherapy [11], which seems
to hold true in Poland as well.
An inherent problem associated with the analysis of
patients undergoing RTx from a centre-based perspec-
tive is the lack of data on the actual diagnosis time. This
‘grey zone’ is caused by a distributed network of hospi-
tals and clinics responsible for the diagnostic process
and their own waiting times and delays. This could con-
tribute to a spuriously shorter median survival and
poorer OS, which may be of particular concern in cases
of rapidly growing, aggressive tumours such as glioblast-
oma [12] or lung cancer [13]. Such delays are notori-
ously common, depend on cancer stage [14], and may
have clinical consequences in the form of reduced odds
of survival or a missed window of opportunity for radical
treatment, as suggested in the study by Wai et al. [13].
However, in contrast to a British study showing a con-
stantly increasing waiting time for breast cancer RTx
[15], in our centre, the number of patients in RTx in-
creased proportionally with the number of newly diag-
nosed cancer cases, suggesting that the availability of
RTx did not decline. This may have been a result of
shorter waiting times or allocation of more resourcesing RTx (both palliative and radical) during the analysis period
rban areas of the Lodz voivodeship administrative region, calculated
Figure 4 (See legend on next page.)
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Figure 4 Kaplan-Meier survival curves depicting changes of overall survival in the studied group, depending on the year of
radiotherapy initiation (A); Kaplan-Meier survival curves for patients undergoing radical RTx for breast, prostate, cervical, or uterine
cancer and non-Hodgkin lymphoma – five of the ten most frequent diagnoses with the best overall survival (B), and for lung, brain,
laryngeal, bladder and rectal cancer – five of the ten most frequent diagnoses with the poorest overall survival (C).
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Health Fund (NFZ) the mean waiting time for radiother-
apy start in October 2014 in Lodzkie Voivodeship was
39 days [16]. Moreover, the changing structure of radically
and palliatively treated patients suggested that the delay
between histopathological diagnosis and RTx could in fact
decrease, allowing for more individuals to enter radical
RTx, although this requires further, diagnosis-specific ana-
lyses. Another explanation of this shift would be the avail-
ability of more refined techniques which impact the
decision making process and make more patients to be
treated radically. The percentage of patients who required
palliative treatment initially was far greater than estimated
for Australian cohort [17]. It is probably explainable by
higher number of patients diagnosed in later stages of
diseases in Central Europe.
A crucial issue in developing the RTx survival database
was that of coverage provided by the respective regis-
tries. To minimise the number of confounding factors,
we relied on administrative resources. This had its
downsides such as the lack of individual causes of death,
which made it impossible for us to assess cause-specific
survival. Nevertheless, the majority of our cohort com-
prised patients with either breast or prostate cancer,
both of which are characterised by a wide-ranging per-
centage of cancer-attributable causes of death [18,19],
making OS a far more robust and reliable parameter
than cause-specific survival when no detailed clinical
data are available.Table 2 Median Overall Survival (OS) times and 5-year OS rates
in the centre during the analysed period
Radical P
Diagnosis Median OS 5Y OS rate M
Breast 3.46 81.18% 1
Lung 1.05 24.54% 0
Prostate 3.02 83.32% 1
Uterus 4.26 80.14% 0
Cervix 2.71 56.35% 2
Brain 1.50 36.74% 0
Rectum 2.56 52.64% 0
Larynx 2.30 44.93% 1
Bladder 1.39 25.22% 0
non-Hodgkin lymphoma 3.26 70.65% 0
All 2.83 64.80% 0
The last row includes all patients from the dataset, including the top ten diagnosesDue to the database’s gradual development we were un-
able to ascertain patient socioeconomic status in 47.4% of
cases. This may pose problems for long-term comparative
analyses, as other registries such as the Eindhoven Cancer
Registry have been collecting socioeconomic data since
their inception [20] and shown socioeconomic status to be
a major modifier of survival likelihood. The issue of socio-
economic status raises concerns about the apparent de-
cline of treatment availability for patients in rural areas,
which may lead to significant disparities in screening avail-
ability and treatment outcomes [21]. We identified no clear
socioeconomic, administrative or health-related causes that
would restrict access to this group of patients making it
more likely, that the decreased proportion of patients from
rural areas is due to insufficient resources and an increas-
ing number of patients from urban areas entering treat-
ment. This could result in patients migrating to or from
the region, limiting the accessibility to available resources
from the region’s inhabitants. We had no way of determin-
ing the true rate of migration between the Lodzkie Region
and the adjacent Voivodeships. However, as we were able
to discern that amongst the 9322 patients with available
address data the fraction of immigrants from other regions
was lower than 0.5%. It may be possible that the deve-
lopment of roads and better means of transportation in-
creased patient mobility between the regions or improved
access for patients from rural areas, but this remains
speculative since no comparative, time-specific compara-
tive groups are available to discern the impact of thesefor patients undergoing radical or palliative radiotherapy
alliative Whole group
edian OS 5Y OS rate Median OS 5Y OS rate
.11 19.11% 3.12 72.26%
.33 7.19% 0.55 13.80%
.12 23.61% 2.77 73.33%
.96 16.47% 4.18 79.40%
.54 16.00% 0.77 54.21%
.50 10.62% 1.10 29.92%
.78 6.55% 2.16 43.72%
.90 10.95% 0.59 38.35%
.36 9.31% 0.74 16.36%
.44 19.44% 2.73 62.97%
.52 12.87% 2.90 51.03%
listed within the table.
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and travel costs may obviously not be the only limiting
factors restricting the access to medical care for patients
with lower socioeconomic status.
The 5-year OS of patients with prostate cancer under-
going RTx was 73.3%. The overall relative survival esti-
mate for the Polish centres participating in EUROCARE
was of 70.7% [22]. In our group, no measures of net
survival were possible as we did not possess information
about the cause of death, nor total population mortality
stratified by age and sex. Nevertheless, the survival rates
suggested that our population did not differ much from
that reported in the EUROCARE cohort. Given how the
improvement in survival rate correlates with the year of
diagnosis, the differences may be attributed to the delay
in implementation of EUROCARE-4 survival reports
and short-term observation of our patients, as the
EUROCARE-4 cohort was recruited in the 1996–2002
period. German survival estimates from the Robert Koch
Institute calculated for the year 2004 however, showed
similar values to those of EUROCARE-4 [23], leading us
to surmise that our current treatments provide our pa-
tients with probabilities of survival very similar to those
in other western European countries.
The surprisingly good survival of patients with lung can-
cer may, however, be associated with a specific substruc-
ture of histopathological types noted in patients entering
treatment, notably an underrepresentation of small-cell
lung cancers. Other jurisdictions did not show much pro-
gress in improving the prognosis of individuals with lung
cancer, with lower scores occurring in cohorts with greater
representation of this kind of lung cancer [24,25]. Similar
issues complicated a uniform interpretation of brain
tumour therapeutic outcomes, as the registries generally
do not include ICD-10 subcategory codes. Further integra-
tion of the presented dataset with histopathology and
radiological databases will provide more opportunities for
in-depth analyses of specific clinical factors.
In general, time-dependent improvement of OS rates
may result from multiple factors, the most obvious of
which is a changing structure of patients undergoing RTx.
To verify that we evaluated the analysed cohort in terms
of its structure (Additional file 1: Table S1) and patients’
age (Additional file 1: Table S2). We noted that even
despite older patients entering the cohort in the later years
of the analysis, the trend towards better survival was
maintained (Additional file 1: Table S3). Thus, although in
depth analyses for diagnosis-specific groups will be neces-
sary to confirm whether the improvement is evident in all
cancer types, overall it did seem that within our region a
gradual improvement of OS noted over the last decade is
a fact rather than a chance observation.
As the purpose of our study was to present the database
with overall characteristics and outcomes of patientstreated within the centre, we could not as this stage
perform in-depth analyses of clinical and cancer-specific
factors affecting survival. Further analyses will focus on
cancer-specific trends and other factors after the database
is merged with specific clinical datasets or the relevant
data are extracted from patients’ medical records. The
established framework of integrated cancer survival data-
bases will allow for repeated follow-up analyses of the co-
hort in order to evaluate long-term survival.
Conclusion
A minimal increase in the availability of RTx was noted in
the region, with a noticeably growing disparity between
urban and rural areas, the latter being under-resourced.
Availability of RTx for Poland is increasing, although still
below the optimal levels reported by other European aca-
demic RTx centres. Survival of patients undergoing radical
RTx gradually improved throughout the analysed period,
although it is still below the level achieved by leading RTx
centres, potentially due to delayed diagnosis or other
factors necessitating further in-depth analyses.
Additional file
Additional file 1: Table S1. The numbers of patients that initiated
radiotherapy during the analysed period. The ten most frequent diagnoses
are enumerated separately, and show a marked increase in the numbers of
patients with breast and prostate cancer referred to the RTx centre. The
number of patients for 2012 covers the period January-June 2012 which
is why no percentages of the National Cancer Registry (NCR) data are
presented. Percentages in the third column represent the fraction of
patients with newly diagnosed cancer who underwent radiotherapy.
Percentages in columns for the ten most frequent diagnoses represent
the fraction of all patients undergoing radiotherapy in a particular year.
Table S2. Age of patients entering radiotherapy throughout the analysis
period. Statistically significant trends of increasing age of patients were noted
amongst breast, lung, prostate, uterine corpus, brain, rectum and bladder
cancers (R coefficients and p values within main text). Table S3. Multivariate
survival analysis results – lung cancer was chosen as the reference class for
the “Diagnosis” categorical variable. Year was modelled in as a continuous
variable which was consistent with the observed pattern of survival
improvement. Models with year of diagnosis treated as a categorical variable
produces a similar result (data not shown). HR – Hazard ratio, 95% CI – 95%
confidence interval. Figure S1. Milestones of centre development, number
of treated patients per year and equipment purchases. The blue bar represents
the analysis period. Figure S2. Distribution of the top 10 diagnoses amongst
patients undergoing radical (2a) and palliative RTx (2b).
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